The French Biopharmaceutical Group LFB S.A. Has Announced the First-in-Man Injections of Its First Two Therapeutic Monoclonal Antibodies and the Filing of BLAs for a New-Generation Immunoglobulin and a Fibrinogen

LES ULIS, France--(BUSINESS WIRE)--During Q4 2008, two monoclonal antibodies developed by LFB's R&D division (an anti-D monoclonal and a batch of anti-CD 20) both achieved a significant development milestone - first-in-man administration.